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Taiwan has one of the highest levels of antibiotic-resistant pneumococcus in the world. Pneumococcal iso-
lates not susceptible to penicillin first appeared in Taiwan in 1986; in 1995 an increase in the prevalence of
nonsusceptibility to penicillins, extended-spectrum cephalosporins, trimethoprim-sulfamethoxazole, and
macrolides as well as multidrug resistance began to be recognized. With the persistence of antibiotic
selective pressure, resistance in some antibiotics reached a high plateau (β -lactam antibiotics) or contin-
ued to increase (macrolides), while novel resistance (fluoroquinolones) emerged in the last 3 years. Wide-
spread distribution of some novel resistant 23F and 19F clones (and the international epidemic of 23F
clones) contributes further to the rapid increase of resistance. Because Streptococcus pneumoniae is a
major pathogen that causes community-acquired lower respiratory tract infections and meningitis in adults
and children, antibiotic-resistance in this organism is a serious problem. 
or more than a century, Streptococcus pneumoniae has
been known as the major bacterial pathogen in humans,
causing substantial illness and death (1,2). Before 1967, this
organism was uniformly susceptible to penicillin. In the early
1990s, pneumococcal isolates appeared that exhibited a high
level of resistance to penicillin and other β -lactam antibiotics
(1). The widespread emergence of this resistance in many
countries has become a major concern in recent years. The
persistence of high antibiotic selective pressure in the commu-
nity and international spread of epidemic or countrywide cir-
culation of endemic multiresistant clones have substantially
contributed to the crisis of resistance (3). This resistance has
complicated treatment options and increased the likelihood of
treatment failure (2).
The Asian region is one of the epicenters for pneumococ-
cal resistance, and Taiwan has become the focus of pneumo-
coccal resistance since 1996, particularly after several reports
documented the alarmingly high prevalence among clinical
isolates of resistance to β -lactam antibiotics and macrolides
(4–12). The Center for Disease Control under the Department
of Health in Taiwan established an active surveillance program
in 1998 to study the epidemiologic features of invasive pneu-
mococcal diseases in Taiwan. Furthermore, a nationwide sur-
veillance system for antimicrobial resistance involving 12
major teaching hospitals (Surveillance from Multicenter Anti-
microbial Resistance in Taiwan [SMART]) has also tracked
the trends of pneumococcal resistance annually since 2000. In
this report, we will discuss the trends of pneumococcal resis-
tance, evidence of dissemination of resistant clones, and sub-
stantial community use of antibiotics, and highlight critical
resistance problems.
Disease Burden and Severity
The incidence of invasive infections caused by S. pneumo-
niae in Taiwan is still unknown, although several studies
regarding invasive pneumococcal infections in adults and chil-
dren have been reported (9,13–19). The overall mortality rate
(42.5%) for elderly patients (>65 years of age) with invasive
infections (bacteremia, pneumonia, pleural empyema, menin-
gitis, septic arthritis, and peritonitis) was higher than the rates
for patients 19–64 years of age (22.4%) and for children
(8.1%) (9). Some factors, such as the presence of serotype 3
strain, shock as initial presentation, and multilobar pneumonia,
were significantly associated with death from invasive infec-
tions (14,15). Another report from central Taiwan indicated
that the overall mortality rate for children with invasive pneu-
mococcal infections was 20.3%, and in 53.3%, the infections
progressed rapidly to death (18). Other studies found that 70%
to 80% of adult patients with invasive pneumococcal disease
had underlying diseases (malignancies, followed by conges-
tive heart failure and diabetes mellitus) (14,15). Patients with
HIV infection or multiple myeloma in whom invasive pneu-
mococcal infection developed were extremely rare (14,13–20).
No significant difference was found in the mortality rates of
patients with penicillin-susceptible (PSSP) and those with pen-
icillin-nonsusceptible  S. pneumoniae (PNSSP) infections
(9,14,15,18). 
The prevalence of this organism that causes community-
acquired pneumonia or meningitis in adults or children is
obscure. Several reports have indicated that this organism
causes 19% to 33% of infections that results in bacterial men-
ingitis in children (21–23). In one study of adult patients, 28%
of the community-acquired bacterial meningitis were caused
by S. pneumoniae, the highest proportion after that was by
Klebsiella pneumoniae (33%) (24). The incidence (cases per
100,000 emergency visits) of pneumococcal meningitis at
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National Taiwan University Hospital was 2.8 in 1997–1998
(24). In other study, S. pneumoniae accounted for 21.8% of
bacterial pathogens isolated from middle ear fluid from 243
children with acute otitis media (25). 
Antimicrobial Resistance
Resistance to Penicillin and Other β -lactam Antibiotics
The first clinical isolate of S. pneumoniae not susceptible
to penicillin was reported in 1986 (26). At National Taiwan
University Hospital, a clinical isolate of PNSSP might have
also been first seen in 1986 (the disk used for determining pen-
icillin susceptibility was not the standard 1-µg disk). A step-
wise decline in the annual rates of susceptibilities to penicillin
from 1981 to 2000 at National Taiwan University Hospital
(disk susceptibility data from all sites of isolates) (1) and a
high prevalence (60%–84%) of clinical PNSSP isolates were
noted throughout the island (disk susceptibility data from all
sites of isolates) (12).
The table summarizes the results of dilution susceptibility
tests for S. pneumoniae isolated from various clinical speci-
mens (6–8, 10) and normally sterile sites (9) of patients seen
from 1996 to 2000. The results were similar to those deter-
mined by the disk diffusion method (12). The proportions of
high-level resistance to penicillin (MIC >2  µg/mL) varied
from 8% to 33%; however, isolates exhibiting an MIC of peni-
cillin of >4 µg/mL accounted for <12%. About 60% of isolates
with intermediate resistance to penicillin also had intermediate
resistance to cefotaxime or ceftriaxone, and nearly all isolates
resistant to penicillin were also not susceptible to those two
agents (6–9). The resistance level was higher among nasopha-
ryngeal isolates from colonized children (71%) or among iso-
lates from children with invasive conditions (such as
bacteremia, pneumonia, meningitis, peritonitis, and empyema
thoracis) than those from adults with invasive conditions (76%
vs. 45%) (chi-square test, p=0.0000009) (5,9). About 50% of
isolates from blood or cerebrospinal fluid samples were not
susceptible to penicillin (6,7,9). Among isolates recovered
from patients hospitalized in the intensive care units from five
major teaching hospitals in Taiwan, 58% were not susceptible
to penicillin, 33% were not susceptible to cefotaxime, and
21% showed intermediate resistance to imipenem (10). 
Resistance to Macrolides
A similar trend of decreased annual rates of susceptibility
for S. pneumoniae was also observed in erythromycin. (Table
and Figure 1). Overall, the prevalence of clinical isolates of S.
pneumoniae not susceptible to erythromycin was 67% to
100% island-wide (12). Only about one-third of the erythro-
mycin-resistant isolates exhibited M-phenotype (27).
Resistance to Fluorquinolones or Other Antibiotics
Isolates not susceptible to ciprofloxacin (MIC >4 µg/mL)
might have first been noted in 1996, but the first clinical iso-
late that was highly resistant to ciprofloxacin (MIC >32 µg/
mL) and other newer fluoroquinolones was documented in
1999 (6,8,28,29). This isolate had mutations in genes gyrA and
parC and also possessed an efflux mechanism (28). Isolates
not susceptible to trimethoprim-sulfamethoxazole accounted
for 60% to 90% (6–10). All isolates are susceptible to vanco-
mycin and linezolid, but some strains were resistant to quinu-
pristin-dalfopristin (10,29). More than 90% of PNSSP isolates
were also resistant to multiple antibiotics (resistant to at least
three classes of antibiotics) (6–10). 
Several factors limit our conclusions regarding the trends
of pneumococcal resistance in Taiwan. First, data on antibiotic
resistance gained from disk diffusion testing in some studies
are not optimal because such studies tend to overestimate pen-
icillin resistance compared with estimates determined by the
dilution method. Second, studies that report resistance data of
a mixture of invasive and noninvasive isolates and of isolates
from different location for different years make it hard to
assess the trends over time since resistance may vary with sites
of isolates and geographic location. Third, resistance data from
one hospital cannot be compared with data from larger popula-
tions since single hospitals may have more referral bias for
severe cases and do not necessarily represent the phenomenon
of the larger population. 
Spread of Resistant Clones
Although one report has supported the idea that the interna-
tional epidemic (Spanish 23F) clone was introduced and dif-
fused in Taiwan (30), multiple domestic and novel clones (23F,
19F, and 6B), which have exhibited high-level resistance to pen-
icillin, extended-spectrum cephalosporins, and macrolides, con-
tinuously circulate in our community (9,31,32). Two penicillin-
resistant clones that acquired separate mechanisms of macrolide
resistance, i.e. Taiwan-23F clone isolates exhibiting high-level
resistance to erythromycin with an MIC of >256 µg/mL
(ermAM genes mediated) and Taiwan-19F clone isolates with
erythromycin resistance shown by an MIC of 1.5–8 µg/mL
Figure 1. Prevalence of susceptibility to five antimicrobial agents for
Streptococcus pneumoniae isolates at the National Taiwan University
Hospital, 1981–2001. Susceptibility testing was performed with the disk
diffusion method. For penicillin susceptibility testing, the 10-U penicillin
disk was used from 1981 to 1989, and the 1-µg oxacillin disk since
1990.Emerging Infectious Diseases  •  Vol. 8, No. 12, December 2002 1489
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(mefE gene–mediated), have already spread (30). Isolates
belonging to the same clone caused various invasive diseases of
different patients who lived in different parts of Taiwan, and
resulted in bacteremic pneumonia in siblings (9,31,33). The
spread of an endemic and highly resistant 23F clone (penicillin
MIC, 4 µg/mL and erythromycin MIC, >256 µg/mL) in one day
care center was also reported (34). The spread of Taiwan clones
to other parts of the world (Taiwan 19F-14 and Taiwan-6B
clones to Hong Kong and United Kingdom; Taiwan 19F-14 to
the United States) has also been documented (30,35,36).
Although the dissemination of fluoroquinolone-resistant strains
has been documented in Hong Kong and Brooklyn, New York
(37,38), to date, the clonal spread of these resistant strains has
not been found in Taiwan.
Impact of Resistance on Antimicrobial Therapy
A high dose of intravenous penicillin G is still recom-
mended as one of the primary drugs of choice for the empirical
treatment of patients with community-acquired pneumonia
who need hospitalization because about 10% of our clinical
isolates have an MIC of penicillin of ≥ 4 µg/mL (6–10,39).
MIC testing, mostly by the E-test, for penicillin-nonusceptible
(oxacillin 1-µg disk) isolates recovered from respiratory secre-
tion or blood specimens from patients without meningitis, is
always performed in most teaching hospitals in Taiwan (39,
40). Obviously, the guidelines for the treatment of community-
acquired pneumonia in adults recommended by the American
Thoracic Society in 2001 (41) and the Infectious Diseases
Society of America in 2000 (42), as well as suggestions for the
management of sinusitis, otitis media, and chronic bronchitis,
which include one macrolide alone as the drug of choice or as
an alternative antimicrobial agent, are inappropriate in Taiwan.
This is because of the high incidence of macrolide resistance
and the high proportion of MLSB-phenotype among these
resistant isolates. 
Serotype Prevalence and Vaccine Coverage
Figure 2 illustrates the distribution of six major serogroups
or serotypes of S.  pneumoniae isolates from 1984 to 1998
(4,6,7,9,19,43). The frequencies of serogroups (serotypes) 23
Table. Summary of dilution susceptibilities for Streptococcus pneumoniae isolates, Taiwan, 1996–1999
Antimicrobial agent
% of nonsusceptible isolates (intermediate/resistant)
1996–1997a (n=200) 1996–1997b (n=550) 1998–1999c (n=267) 1998–1999d (n=288) 2000e  (n=24)
Penicillin 61 (28/33) 56 (43/13) 76 (51/25) 56 (34/22) 58 (50/8)
Amoxicillin (-clavulanate) 50 (34/16) 33 (32/1) 22 (12/10) —
Cefuroxime — — 67 (16/51) 43 (6/37) —
Ceftriaxone (cefotaxime) 39 (16/23) 13 (11/2) 56 (54/2) 25 (15/10) 33 (29/4)
Cefepime 43 (19/24) — — — 42 (21/21)
Imipenem — 15 (13/2) — 14 (14/0) 21 (21/0)
Meropenem — — — — 4 (4/0)
Erythromycin 83 (6/77) 74 (5/69) — 76 (4/74) —
Azithromycin — 78 (4/74) 94 (4/90) 78 (6/72) —
Clarithromycin 90 (9/81) — 95 (6/89) — —
Trimethoprim-sulfamethoxazole 87 (6/81) — 65 (33/32) 71 (30/41) —
Ciprofloxacinf 2 — 4 —  0
Levofloxacin — 1 (0/1) —  0
Moxifloxacin 0 — 1 (0/1) — 0
Rifampin 0 7 (7/0) — — —
Vancomycin 0 0 — 0 0
Quinupristin-dalfopristin — — 8 (6/2) — 42 (38/4)
Linezolid — — 0 —  0
aData adopted from reference 6. All isolates were recovered from various clinical specimens (60% of isolates from respiratory secretions and 27% from blood samples) of patients 
treated at the National Taiwan University Hospital (NTUH).
bData adopted from references 7. All isolates were recovered from various clinical specimens (36.7% from sputa and 42.3% from sterile sites) of patients treated at 14 major hospitals 
in Taiwan.
cData adopted from references 8. All isolates were recovered from various clinical specimens, including 86.4% from respiratory secretions and 8.8% from sterile sites (cerebrospinal 
fluid, blood, ascites and pleural fluid) of patients treated at five teaching hospitals in Taiwan.
dData adopted from reference 9. All isolates were recovered from normally sterile sites (cerebrospinal fluid, blood, ascites and pleural fluid) of patients treated at all major hospitals in 
Taiwan.
eData adopted from reference 10. All isolates were recovered from various clinical specimens (12 isolates were recovered from non-respiratory secretions) of patients treated at five 
teaching hospitals in Taiwan.
fCiprofloxacin MIC >4 µg/mL.SYNOPSIS
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(23F) and 19 (19F) increased remarkably, whereas those of
serotypes 14, 3, and 1 declined. Some unusual serotypes (sero-
types 20, 11, 7, and 8) appeared to emerge in southern Taiwan.
No relationship was found between the serogroup or serotype
distribution of isolates and the patients’ ages (p >0.05) (6,7,9).
PNSSP exhibited resistance to isolates from various sero-
groupsor serotypes. Among them, serogroups 11 and 23 iso-
lates had the highest incidence of penicillin nonsusceptibility
and multidrug resistance. However, serotype 3 isolates (0%–
22%) and serotype 20 (11%) isolates had lower rates of non-
susceptibility to penicillin (4,6,9,19). In general, more than
90% of isolates causing invasive infections were included in
the serogroups or serotypes covered by the 23-valent pneumo-
coccal and 7-valent conjugate vaccine (4,9). 
Extent of Antibiotic Use in the Community
Before 1995, few regulations regarding antibiotic use
existed for physicians in primary care clinics or hospitals. Fur-
thermore, many antibiotics could easily be obtained at drug-
stores without a prescription. Although the medical payment
has been regulated by the National Health Insurance program,
implemented in Taiwan in 1995, antibiotics are still commonly
used and seem to be overprescribed in primary care units (44).
From 1996 to 1999, about 12% to 14% of total patient-visits in
primary care units had antibiotic use. The common cold
(32.3%) was the most frequent diagnosis for which antibiotics
were prescribed. Penicillins (35.4%), cephalosporins (26.5%),
and macrolides (21.6%) were the most commonly prescribed
classes of antibiotics (44). In 1999, a reported point prevalence
rate of about 7.5% among healthy high school students and
healthy ambulatory elderly persons who had antimicrobial
activity in their urine suggested that this may be the baseline
for antibiotic use in the community (45). Surprisingly, over
half of the patients who came to the emergency department of
a large teaching hospital in Taiwan had taken antibiotics within
the previous 12–48 hours. With the increasing and highly
selective pressure of antibiotic usage in our community, the
crisis of resistance continues to exist. 
In the new millennium, the Center for Disease Control
under the Department of Health in Taiwan has made nation-
wide surveillance of antimicrobial resistance and strict control
of antibiotic usage major tasks. The new regulations for antibi-
otic prescription, established by the Bureau of National Health
Insurance in 2001 (44), restrict the inappropriate use of the so-
called first-line antibiotics (first-generation cephalosporins,
macrolides, and gentamicin) for treating various infections,
particularly the trivial upper respiratory tract infection. The
use of the 23-valent pneumococcal vaccine, especially among
high-risk adults and older persons, is encouraged, and new
protein-conjugate vaccines will be introduced in the near
future. 
Conclusion
Taiwan has one of the highest levels of antibiotic resistant
pneumococcus in the world. With the increase in international
travel, the interchange of resistant clones among countries is
unavoidable and the widespread distribution of these clones is
expected. Strategies to limit the upsurge of resistant pneumo-
coccus include improved surveillance, reduced antibiotic
usage, and increased vaccination of persons at high risk. The
judicious use of antimicrobial agents is necessary to avoid pro-
viding a selective advantage for resistant organisms. The active
surveillance of resistant organisms can help track local resis-
tance problems, prevent the future dissemination of these
organisms, and provide options appropriate for empiric therapy. 
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